Editorial ArticleDrug Discovery & Development
The hidden coagulation risk in plasma-derived biologics
Explore how specialist hemostatic risk testing can prevent costly clinical failures in plasma-derived biologics
The process of proving an assay to be sensitive with respect to the target is known as assay development. The assay should be able to characterize novel compounds and measure the potency of these compounds against a validated biological target.
Explore how specialist hemostatic risk testing can prevent costly clinical failures in plasma-derived biologics